Inhibrx CEO Mark Lappe Purchases $2.6 Million Worth of Shares
Mark Lappe, the founder and CEO of Inhibrx Biosciences (NASDAQ:INBX), purchased 25,000 shares for a total value of $2.6 million on September 8, 2026. The transaction was executed through multiple trades at prices ranging from $98.88 to $112.44 per share, with an average cost basis of $105.82. This acquisition increased Lappe's total beneficial ownership in the company to approximately 950,000 shares, representing about 6% of Inhibrx’s outstanding equity. The CEO holds all his shares indirectly through trusts and retirement accounts, including the Lappe Family Trust and a Roth IRA. Despite reporting a trailing twelve-month net loss of $138.2 million, Inhibrx maintains a market capitalization of $1.4 billion as it continues to develop its pipeline of biologic therapeutics using proprietary modular protein engineering platforms. The purchase is seen by some investors as a sign of confidence in the company’s future prospects and platform technology.
Tickers: $INBX
Topics: biotech CEO activity stock transactions